You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Product Overview - For GB Members of the Public

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. More details on how to report side effects can be found at the bottom of this page.

XEVUDY contains the active substance sotrovimab. Sotrovimab is a monoclonal antibody, a type of protein designed to recognise a specific target on the SARS-CoV-2 virus, the virus that causes acute COVID-19 infection.

Xevudy is used to treat symptomatic acute COVID-19 infection in adults and adolescents (from 12 years and weighing at least 40 kg). It targets the spike protein that the virus uses to attach to cells. Xevudy can help your body overcome the infection and prevent you from getting seriously ill.

Trade marks are owned by or licensed to the GSK group of companies.

- This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the Patient information leaflet.
You can also report side effects directly via the Yellow Card Scheme at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store.
By reporting side effects you can help provide more information on the safety of this medicine.